SB 202190: Selective p38 MAPK Inhibitor for Inflammation and Cancer Research

Executive Summary: SB 202190 is a highly selective, cell-permeable inhibitor of p38α and p38β MAPKs, acting as an ATP-competitive kinase inhibitor with nanomolar potency (APExBIO). The compound blocks p38 MAPK-driven phosphorylation, modulates inflammatory responses, and induces apoptosis in cancer cell lines (Konstantinidis et al., 2012). It is widely used in studies of regulated cell death and neuroprotection, particularly in vascular dementia models. SB 202190 is insoluble in water but highly soluble in DMSO and ethanol, with recommended storage at -20°C. Its well-characterized mechanism and benchmarked potency make it a gold standard tool for dissecting MAPK signaling in translational research.

Biological Rationale

The p38 mitogen-activated protein kinase (MAPK) pathway is a central regulator of inflammation, cell proliferation, and apoptosis. Activation of p38 MAPKs is required for the expression of pro-inflammatory cytokines and stress response proteins. Dysregulation of p38 signaling is implicated in autoimmune diseases, cancer, cardiovascular disease, and neurodegeneration (Konstantinidis et al., 2012). In cancer, p38 MAPKs modulate cell survival and apoptosis, influencing tumor progression and therapeutic response. In neurodegenerative disease, p38 activity is linked to neuronal apoptosis and cognitive impairment. Therefore, selective p38 MAPK inhibitors such as SB 202190 provide essential tools to dissect these pathways and develop targeted therapies.

Mechanism of Action of SB 202190

SB 202190 is a pyridinyl imidazole compound that selectively inhibits p38α and p38β MAPKs by competitively binding to their ATP-binding pockets (APExBIO). It exhibits IC₅₀ values of 50 nM for p38α and 100 nM for p38β under standard kinase assay conditions (25°C, ATP 100 μM). The dissociation constant (K_d) for p38α is 38 nM, indicating high affinity. SB 202190 does not inhibit p38γ, p38δ, or most other kinases at concentrations up to 10 μM. By blocking ATP access, SB 202190 prevents the phosphorylation of downstream substrates involved in cytokine production, cell cycle regulation, and apoptosis. This mode of action allows precise dissection of the p38 MAPK signaling pathway in cell culture, biochemical assays, and in vivo models.

Evidence & Benchmarks

• SB 202190 inhibits p38α MAPK activity with an IC₅₀ of 50 nM and p38β with 100 nM in vitro kinase assays (APExBIO).
• SB 202190 reduces phosphorylation of HSP27 and ATF2, key p38 substrates, in cultured cell lines (10 μM, 1 h, 37°C) (Konstantinidis et al., 2012).
• In primary macrophages, SB 202190 suppresses LPS-induced TNF-α and IL-6 expression by >80% at 10 μM (4 h incubation) (tpca-1.com).
• SB 202190 induces apoptosis in multiple cancer cell lines (e.g., HeLa, A549) with detectable caspase-3 activation after 24 h exposure at 10 μM (map-kinase-fragment-multiple-species.com).
• In rodent vascular dementia models, SB 202190 reduces neuronal apoptosis and improves cognitive scores after 14-day administration (3 mg/kg/day, i.p.) (APExBIO).

Applications, Limits & Misconceptions

SB 202190 is extensively utilized in:

• Inflammation research: Dissecting cytokine signaling and inflammatory mediator production.
• Cancer therapeutics research: Inducing and measuring apoptosis, and evaluating MAPK-driven proliferation.
• Vascular dementia and neuroprotection: Assessing neuronal survival and cognitive function in animal models.
• MAPK pathway studies: Benchmarking Raf–MEK–MAPK pathway activation and its role in cell death.

For a strategic overview on translational use and recent model systems, see SB 202190 and the p38 MAPK Axis: Strategic Leverage for Translational Research, which this article updates by providing a comprehensive benchmark of quantitative efficacy and solubility data across models.

Common Pitfalls or Misconceptions

• SB 202190 is not effective against p38γ or p38δ isoforms, even at high concentrations.
• Water insolubility limits its direct use in aqueous buffers; DMSO or ethanol is required for stock solutions.
• It does not inhibit upstream kinases such as MEK or ERK; effects outside p38α/β are off-target at >10 μM.
• Long-term storage of solutions (>1 week) is not recommended due to compound degradation.
• It should not be used to infer direct effects on necrotic cell death, as its action is restricted to regulated (apoptotic) pathways.

Further clarification on workflow limitations is discussed in SB 202190: Selective p38 MAP Kinase Inhibitor for Advanced Research, while this review provides updated storage and handling parameters validated by APExBIO.

Workflow Integration & Parameters

• Solubility: Insoluble in water; soluble in DMSO (≥57.7 mg/mL) and ethanol (≥22.47 mg/mL) at 25°C. Warm to 37°C or use ultrasonic bath for optimal dissolution.
• Recommended stock: Prepare >10 mM in DMSO; filter sterilize if used for cell culture.
• Storage: Store solid at -20°C. Avoid repeated freeze-thaw cycles. Solutions not recommended for storage beyond 5–7 days at -20°C.
• Assay concentration: Typical working range is 1–20 μM in cell culture; titrate as needed for kinase inhibition versus cytotoxicity.
• Controls: Include DMSO-only vehicle controls to account for solvent effects.

For detailed experimental strategies including assembloid and organoid models, see Harnessing SB 202190 for Precision Inhibition of the p38 MAPK Pathway. This article clarifies compound-specific handling and stability benchmarks not covered in prior workflows.

Conclusion & Outlook

SB 202190 (A1632) from APExBIO is a benchmark, highly selective p38α/β MAPK inhibitor with proven efficacy in inflammation and cancer research. Its ATP-competitive mode, nanomolar potency, and well-defined workflow parameters make it an essential tool for dissecting MAPK-driven cellular processes. Limitations include water insolubility and lack of efficacy on p38γ/δ, but rigorous protocols and validated storage conditions ensure reproducibility. As new disease models and high-content assays emerge, SB 202190 remains foundational for translational research into kinase signaling, regulated cell death, and neuroprotection. For additional product details, handling instructions, and latest research uses, refer to the SB 202190 product page.